COLORADO SPRINGS, Colo., Feb. 12, 2013 /PRNewswire/ -- Cannabis Science, Inc. (NASDAQ OTC: CBIS) has appointed Harold C. Smith, Ph.D., Professor in Biochemistry, Biophysics, and Oncology with secondary appointments as Professor in the Department of Genetics and Pathology and a Member of the Center for RNA Biology at the University of Rochester, School of Dentistry and Medicine, to the Company’s Scientific Advisory Board. At the University of Rochester Dr. Smith directs a research laboratory and teaches undergraduate and medical school courses in biochemistry. He is a member of the RNA Society and a member of the American Association for the Advancement of Science. He received the SUNY at Buffalo‘s Distinguished Alumni Award as well as several awards from the University or Rochester for contributions to the teaching mission and leadership in mentoring. Dr. Smith has been an opinion leader in RNA biology where he established the first Gordon Research conference on RNA Editing. Dr. Smith has also been the recipient of a number of grants, including grants from the Bill and Melinda Gates Foundation, the NIH, the United States Air Force, and the Office of Naval Research. In total, Dr. Smith has received federal and foundation research grants in excess of $6.5 million. Dr. Smith has been an opinion leader in RNA biology where he established the first Gordon Research conference on RNA Editing. Dr. Smith is the author of more than 100 peer-reviewed manuscripts and reviews during his career, exceeding more than 9,973 citations.
Dr. Smith received his Ph.D. from SUNY at Buffalo, following BS and MS degrees from Purdue University and an MA degree from SUNY at Buffalo. Dr. Smith also held post-doctoral positions in biochemistry at SUNY at Buffalo followed by three post-doctoral positions in biochemistry, pharmacology, and medical genetics, respectively, at Baylor College of Medicine.
In addition, Dr. Smith is the Founder and CEO of OyaGen, Inc., a biotech company in Rochester, New York developing novel therapeutics for infectious disease and cancer. OyaGen has raised in excess of $4 million from venture and angel investor sources and two federal grants for assay development.
Dr. Smith stated, “It is my pleasure to join the scientific advisory board of CBIS. In joining the Company’s SAB, I hope to bring over 30 years of research experience in cancer and HIV to assist in developing a clear platform for the commercialization of CS-TATI-1 and CS-S/BCC-1. I look forward to assisting in the realization of bridging macro and microbiology in discovering new applications for the medicinalization of cannabinoids.”
“We are honored to have Dr. Smith join the Scientific Advisory Board of Cannabis Science. Dr. Smith’s broad experience in multidisciplinary biological research and professional development of therapeutics consistent with the goals of the Company make him a tremendously valuable addition to the Cannabis Science team, as we move forward in drug development,” stated Robert Melamede, Ph.D., President and CEO of Cannabis Science.
About CS-TATI-1
Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About CS-S/BCC-1
Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has begun preclinical investigations, which are being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi’s sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” “intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Or
Robert Kane, VP, Investor Relations
1-561-234-6929
rkane@cannabisscience.com
www.cannabisscience.com
SOURCE Cannabis Science, Inc.
